ReviewCurrent opinion in neurobiology2026
Decoding Alzheimer's genetic risk through intercellular communication in the human brain: Lessons from Clusterin.
Review in Current opinion in neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transcriptomic Challenges We Faced with Animal Models for Neurological Disorders.Current issues in molecular biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Late-onset Alzheimer's disease (AD) arises in part from a complex genetic architecture dominated by common, low-penetrance variants, many of which are enriched in glial cells and remain mechanistically unresolved. Unlike the rare coding mutations that contribute to early-onset AD, these common variants often lie in noncoding regions, complicating efforts to link genetic risk to cellular function. Emerging evidence suggests that many glial-enriched risk genes contribute to disease by disrupting communication between glia and neurons. Such interactions are essential for preserving synaptic health and modulating immune responses to pathology. Understanding how polygenic variation perturbs these pathways requires integrative strategies that combine large-scale postmortem brain datasets with experimentally tractable human cellular models. In this review, we highlight recent progress in decoding the cellular impact of AD risk variants through the lens of glial-neuronal communication. We first illustrate how human brain studies have mapped cell-type-specific gene expression and intercellular networks associated with genetic risk. We then discuss how human stem cell-derived co-culture and 3D models are being used to test these hypotheses in controlled experimental systems. As a case study, we focus on CLU (Clusterin), a well-replicated risk locus that modulates glial inflammation, lipid exchange, and neuronal vulnerability. Together, these studies build a scalable, human-centric framework for linking genotype to function and point toward new opportunities for therapeutic discovery rooted in intercellular biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.